S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
NASDAQ:PRCT

PROCEPT BioRobotics (PRCT) Stock Forecast, Price & News

$32.09
-0.46 (-1.41%)
(As of 09/21/2023 ET)
Compare
Today's Range
$31.48
▼
$32.45
50-Day Range
$30.02
▼
$38.59
52-Week Range
$25.29
▼
$47.75
Volume
296,087 shs
Average Volume
378,971 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

PROCEPT BioRobotics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
40.2% Upside
$45.00 Price Target
Short Interest
Bearish
9.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of PROCEPT BioRobotics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$316,120 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.22) to ($1.88) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

443rd out of 965 stocks

Surgical & Medical Instruments Industry

53rd out of 96 stocks

See Top Rated MarketRank™ Stocks Here

PRCT stock logo

About PROCEPT BioRobotics (NASDAQ:PRCT) Stock

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

PRCT Price History

PRCT Stock News Headlines

September 20, 2023 | finance.yahoo.com
PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose
September 15, 2023 | barrons.com
PROCEPT BioRobotics Corp.
September 22, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
September 15, 2023 | americanbankingnews.com
PROCEPT BioRobotics Co. (NASDAQ:PRCT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
September 15, 2023 | americanbankingnews.com
PROCEPT BioRobotics (NASDAQ:PRCT) Rating Reiterated by Truist Financial
September 14, 2023 | msn.com
Truist Securities Reiterates Procept BioRobotics (PRCT) Buy Recommendation
September 12, 2023 | msn.com
PROCEPT BioRobotics gets FDA okay for prostate cancer study
September 12, 2023 | markets.businessinsider.com
B.Riley Financial Sticks to Their Buy Rating for PROCEPT BioRobotics (PRCT)
September 22, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 12, 2023 | finance.yahoo.com
PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer
August 28, 2023 | fool.com
Procept BioRobotics (NASDAQ: PRCT)
August 22, 2023 | finance.yahoo.com
PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan
August 17, 2023 | finance.yahoo.com
PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston
August 16, 2023 | finance.yahoo.com
NorthShore University HealthSystem offers expanded access to treat most common prostate ailment
August 11, 2023 | msn.com
Piper Sandler starts Procept at overweight, cites high growth potential
August 11, 2023 | msn.com
Piper Sandler Initiates Coverage of Procept BioRobotics (PRCT) with Overweight Recommendation
August 11, 2023 | markets.businessinsider.com
PROCEPT BioRobotics (PRCT) Receives a New Rating from Piper Sandler
August 11, 2023 | finance.yahoo.com
Twilio upgraded, Sealed Air downgraded: Wall Street's top analyst calls
August 11, 2023 | msn.com
Procept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate Buy
August 10, 2023 | seekingalpha.com
Procept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate Buy
August 3, 2023 | seekingalpha.com
PROCEPT BioRobotics launches stock offering to raise $125M
August 2, 2023 | finance.yahoo.com
The one-year earnings decline has likely contributed toPROCEPT BioRobotics' (NASDAQ:PRCT) shareholders losses of 14% over that period
August 1, 2023 | finance.yahoo.com
PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock
August 1, 2023 | finance.yahoo.com
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
August 1, 2023 | markets.businessinsider.com
PROCEPT BioRobotics (PRCT) Receives a Buy from Truist Financial
July 28, 2023 | markets.businessinsider.com
Bank of America Securities Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)
July 27, 2023 | finance.yahoo.com
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
See More Headlines
Receive PRCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter.

PRCT Company Calendar

Last Earnings
7/27/2023
Today
9/21/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRCT
CUSIP
N/A
CIK
1588978
Web
www.procept-biorobotics.com
Phone
650-232-7200
Fax
N/A
Employees
428
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$45.00
High Stock Price Forecast
$49.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+40.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-87,150,000.00
Net Margins
-102.87%
Pretax Margin
-102.87%
Return on Equity
-54.25%
Return on Assets
-34.04%

Debt

Debt-to-Equity Ratio
0.34
Current Ratio
6.40
Quick Ratio
5.21

Sales & Book Value

Annual Sales
$75.01 million
Price / Sales
19.37
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.41 per share
Price / Book
7.28

Miscellaneous

Outstanding Shares
45,280,000
Free Float
36,404,000
Market Cap
$1.45 billion
Optionable
Not Optionable
Beta
0.57
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Reza Zadno Ph.D. (Age 68)
    Pres, CEO & Director
    Comp: $1.26M
  • Mr. Kevin Waters (Age 46)
    Exec. VP & CFO
    Comp: $744.1k
  • Ms. Alaleh Nouri (Age 44)
    EVP, Chief Legal Officer & Corp. Sec.
    Comp: $713.61k
  • Mr. Hisham Shiblaq (Age 47)
    Exec. VP & Chief Commercial Officer
    Comp: $757.2k
  • Mr. Mohan F. Sancheti (Age 59)
    Sr. VP of Operations
  • Mr. Matthew James Bacso C.F.A.
    VP of Investor Relations
  • Ms. Minni Vittal
    Sr. VP & Chief People Officer
  • Mr. Bijesh Chandran
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Mr. Barry Templin
    Sr. VP of Clinical & Medical Affairs
  • Dr. Thomas J. Yorkey Ph.D. (Age 61)
    Sr. VP of R&D

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PRCT Stock - Frequently Asked Questions

Should I buy or sell PROCEPT BioRobotics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRCT shares.
View PRCT analyst ratings or view top-rated stocks.

What is PROCEPT BioRobotics' stock price forecast for 2023?

7 analysts have issued 1 year price targets for PROCEPT BioRobotics' shares. Their PRCT share price forecasts range from $42.00 to $49.00. On average, they expect the company's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 40.2% from the stock's current price.
View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts.

How have PRCT shares performed in 2023?

PROCEPT BioRobotics' stock was trading at $41.54 at the start of the year. Since then, PRCT stock has decreased by 22.7% and is now trading at $32.09.
View the best growth stocks for 2023 here.

When is PROCEPT BioRobotics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PRCT earnings forecast.

How were PROCEPT BioRobotics' earnings last quarter?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) announced its quarterly earnings results on Thursday, July, 27th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.01. The firm earned $33.10 million during the quarter, compared to the consensus estimate of $30.25 million. PROCEPT BioRobotics had a negative net margin of 102.87% and a negative trailing twelve-month return on equity of 54.25%.

What ETFs hold PROCEPT BioRobotics' stock?

ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), ALPS Disruptive Technologies ETF (DTEC) and Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ).iShares U.S. Medical Devices ETF (IHI).

What guidance has PROCEPT BioRobotics issued on next quarter's earnings?

PROCEPT BioRobotics updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $131.00 million-$131.00 million, compared to the consensus revenue estimate of $128.50 million.

When did PROCEPT BioRobotics IPO?

(PRCT) raised $126 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share.

What is PROCEPT BioRobotics' stock symbol?

PROCEPT BioRobotics trades on the NASDAQ under the ticker symbol "PRCT."

Who are PROCEPT BioRobotics' major shareholders?

PROCEPT BioRobotics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.70%), State Street Corp (2.35%), Geode Capital Management LLC (1.58%), Allspring Global Investments Holdings LLC (1.38%), Allspring Global Investments Holdings LLC (1.38%) and Mirae Asset Global Investments Co. Ltd. (1.11%). Insiders that own company stock include Alaleh Nouri, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel.
View institutional ownership trends.

How do I buy shares of PROCEPT BioRobotics?

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PROCEPT BioRobotics' stock price today?

One share of PRCT stock can currently be purchased for approximately $32.09.

How much money does PROCEPT BioRobotics make?

PROCEPT BioRobotics (NASDAQ:PRCT) has a market capitalization of $1.45 billion and generates $75.01 million in revenue each year. The company earns $-87,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis.

How many employees does PROCEPT BioRobotics have?

The company employs 428 workers across the globe.

How can I contact PROCEPT BioRobotics?

PROCEPT BioRobotics' mailing address is 900 ISLAND DRIVE, REDWOOD CITY CA, 94065. The official website for the company is www.procept-biorobotics.com. The company can be reached via phone at 650-232-7200 or via email at ir@procept-biorobotics.com.

This page (NASDAQ:PRCT) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -